NI Medical Joins Innovators’ Network at American Heart Association Center for Health Technology & Innovation

NI Medical Joins Innovators’ Network at American Heart Association Center for Health Technology & Innovation

November 3, 2022 Editor 0

NI Medical Joins Innovators’ Network at American Heart Association Center for Health Technology & InnovationNI Medical Joins Innovators’ Network at American Heart Association Center for Health Technology & InnovationAmerican Heart Association consortium advances development of evidence-based health tech solutions.

TEL AVIV, Israel – November 3, 2022 – (Newswire.com)

NI Medical, the inventors of NICaS, the non-invasive hemodynamic monitoring tool, has joined the American Heart Association Center for Health Technology & Innovation’s (the Center) Innovators’ Network. The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions.

The Innovators’ Network is a healthcare-focused technology consortium that connects entrepreneurs, providers, researchers and payers. Innovators’ Network members also have access to the Association’s digital guidelines, recommendations, and best-in-class science as they develop digital healthcare technologies. Members collaborate with the Center in different ways, including the building of models for clinical outcome studies, lowering the significant cost of developing those studies independently, helping connect the science to technology, and providing evidence that a digital platform improves healthcare outcomes – a key concern for providers and payers.

“The Center aims to advance the rapid, efficient, and effective development of healthcare technology,” said Robert A. Harrington, M.D., FAHA, past president of the American Heart Association (2019-2020), volunteer chair of the American Heart Association’s Health Tech Advisory Group for the Center and Arthur L. Bloomfield professor and chair department of medicine, Stanford University. “Joining the Innovators’ Network gives members the opportunity to leverage the consortium and work toward broadening and deepening their engagement in this arena.”

“Excited to become a part of this exceptional network and join forces to deliver our unique solution for heart failure and hypertension patients management,” says Eyal Karev, CEO of NI Medical.

About NI Medical

NI Medical joins the Innovators’ Network, bringing with them NICaS, a non-invasive, cost-effective and highly validated hemodynamic management solution. 

NICaS is the only whole-body bioimpedance tool that has extensive clinical validation and accuracy capabilities equal to the gold standard (Thermodilution) with extremely high reproducibility. The solution’s greatness lies in its ability to provide the cause for the patient’s hemodynamic instability – and not only the symptom.

NI Medical presents significant expertise in bioimpedance technology globally. Having developed NICaS, the only whole-body noninvasive hemodynamic management solution, the company has been active globally and in the U.S. market for several years. The solution allows for improved personalized patient therapy, mainly in heart failure and hypertension disease management, as well as other chronic conditions. The solution is highly validated from technology, clinical and commercial perspectives. 

MEDIA CONTACT:

Jenny Chernikh
[email protected]

Contact Information:

Jenny Chernikh

Marketing Manager

[email protected]

+9720503032998

Press Release Service
by
Newswire.com

Original Source:

NI Medical Joins Innovators’ Network at American Heart Association Center for Health Technology & Innovation

Imagene Named ‘Oncology Innovation of the Year’ at 2022 BioTech Breakthrough Awards

Imagene Named ‘Oncology Innovation of the Year’ at 2022 BioTech Breakthrough Awards

November 3, 2022 Editor 0

Imagene Named ‘Oncology Innovation of the Year’ at 2022 BioTech Breakthrough AwardsImagene Named ‘Oncology Innovation of the Year’ at 2022 BioTech Breakthrough AwardsAnnual Awards Program Recognizes Innovation in the Global Life Sciences and Biotechnology Industry

TEL AVIV, Israel – November 3, 2022 – (Newswire.com)

Imagene, an emerging leader in the field of AI-based precision oncology, today announced it has been selected as “Oncology Innovation of the Year” in the second annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe.

The mission of the annual BioTech Breakthrough Awards program is to conduct the industry’s most comprehensive analysis and evaluation of the top companies, solutions and products in the life sciences and biotechnology industry today. This year’s program attracted more than 1,350 nominations from over 12 different countries throughout the world. Imagene’s AI-based Biomarker Detection was chosen as a breakthrough innovation in the field of Medical Technology.

Imagene is a pioneer startup in the Digital Genomics space. Using computer vision algorithms, the company can detect in real-time cancerous genomic alterations directly from the biopsy slide (H&E) scanned image. The idea behind Imagene’s innovative development aligns with the notion that actionable (driver) genomic alterations will have a morphological effect on the tissue in a resolution that is impossible for the human eye to detect, but AI and deep learning models can. 

“We are honored to be recognized among these great Life Science and BioTech innovators as we continue to advance precision oncology in the fight against cancer,” said Dean Bitan, co-founder and CEO at Imagene. “The cancer diagnosis process has evolved to include crucial genomic information; however, long turnaround time, tissue, and cost make its availability limited. Identifying gene alterations is key for improving patient care and guiding targeted therapeutic decisions; physicians should be able to make optimal treatment decisions in a timely and accurate manner. The availability of rapid molecular analysis can sometimes be the difference between life and death.”

“Based on the NCCN guidelines, the identification of patient-specific actionable genomic alterations serves as the basis foundation of precision oncology and is utilized routinely for optimal and personalized treatment decisions that drive higher response and mortality rates. The need to use biological specimens and the extended time needed for the analysis and interpretation, as well as inadequate tissue biopsies result in patients not getting life-saving treatment quickly enough,” said Bryan Vaughn, Managing Director of BioTech Breakthrough Awards. “Imagene’s innovative solution opens the path to fast and accurate cancer diagnosis, demonstrating the huge advancement that AI-based genomic testing can offer to cancer patients’ care. All our deep congratulations on winning ‘Oncology Innovation of the Year!'” 

Imagene has developed 28 different models for actionable alterations across eight cancer types, including Lung, Colorectal, Bladder, Breast, Ovary, Hematology, Thyroid, and brain cancer. The detection accuracy level aligns with the current gold-standard methodologies showing an average sensitivity that is superior to the standard of care. Imagene real-time image-based biomarker detection takes about two minutes, it reduces cost and time significantly with high scalability and seamless integration with routine workflows.

About Imagene

Imagene is a precision oncology diagnosis company with the mission to assist cancer patients in receiving the optimal treatment medicine can offer by leveraging AI to detect, in real-time, a broad range of cancerous biomarkers and clinical insights using only digitized biopsy images. Its multidisciplinary team is composed of a diverse group of experts from the fields of science, medicine, and deep learning. Imagene collaborates with top-tier medical centers and pharmaceutical companies worldwide, striving for fast and accurate cancer diagnosis, profiling patients for clinical trials, and accelerating the drug development process. For more information, visit Imagene-AI.com.

About BioTech Breakthrough

Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the BioTech Breakthrough Awards program is devoted to honoring excellence in life science and biotechnology solutions, services, and companies. The BioTech Breakthrough Awards provide public recognition for the achievements of biotechnology companies and products in categories including BioPharma, Genomics, Therapeutics, Food Science and BioAgriculture, and more. For more information, visit BioTechBreakthroughawards.com

Contact Information:

Avital Rabani

Head of Marketing

[email protected]

Press Release Service
by
Newswire.com

Original Source:

Imagene Named ‘Oncology Innovation of the Year’ at 2022 BioTech Breakthrough Awards

Optimize Health Joins Panda Health’s Marketplace to Deliver Leading Remote Patient Monitoring Solution to Health Systems

Optimize Health Joins Panda Health’s Marketplace to Deliver Leading Remote Patient Monitoring Solution to Health Systems

November 2, 2022 Eric Jones 0

Optimize Health Joins Panda Health’s Marketplace to Deliver Leading Remote Patient Monitoring Solution to Health SystemsOptimize Health Joins Panda Health’s Marketplace to Deliver Leading Remote Patient Monitoring Solution to Health SystemsEntry in the Marketplace enables providers and enterprise-scale healthcare systems to deliver a personalized, continuum of care that connects in-office and at-home solutions

SEATTLE – November 2, 2022 – (Newswire.com)

Optimize Health, a leader in the rapidly growing remote patient monitoring (RPM) industry, today announced their status as a Panda Awarded Supplier in the RPM solution category and entry into Panda’s Digital Health Marketplace. Panda’s Marketplace offers a trusted, centralized place for health system professionals to search, research, and select the best digital health solutions for their businesses and patients.

Optimize Health’s leading RPM solution is now available to Panda Health’s network of health systems and enables them to find the solutions that easily integrate with their existing technologies and provide proven results for their practice and patient outcomes. 

“Panda Health shares Optimize Health’s mission to make digital healthcare solutions easily accessible, and help accelerate the digital transformation of patient-centered care,” said David Harvey, CEO at Panda Health. “By bringing Optimize Health into our Marketplace, we are helping providers deliver personalized care that drives better outcomes for their patients, with stronger ROI for healthcare organizations, and optimal results for practices.” 

Benefits of Optimize Health’s RPM Solution

Optimize Health offers a full-service solution that delivers better patient outcomes via: 

  • Leading remote care technology: Platform centralizes patient data and highlights the most critical information first, facilitating outcome-positive workflows across patients
  • Managed servicesA complete suite of services to support clients at every stage of their RPM journey–from patient identification to continuous remote patient onboarding
  • Security and complianceOptimize Health’s program and organization is HITRUST certified, complying with the industry standard of security and privacy for healthcare solutions

“We are excited to partner with Panda Health by being a part of their innovative digital healthcare Marketplace,” said Todd Haedrich, CEO of Optimize Health. “Our inclusion in their Marketplace allows their network of hospitals and health systems to leverage RPM and remote care solutions to expand the quality and quantity of meaningful health care interactions outside of in-person office visits.” 

To learn more about Optimize Health’s RPM solution in Panda Health’s Marketplace, please visit panda.health.

About Optimize Health

Optimize Health is a leading provider of remote patient monitoring (RPM) solutions, helping provider groups across the country deliver high-quality care beyond the practice walls. Through a powerful combination of platform technology, connected devices, and expert support, we help clients and patients build deeper bonds outside of the office visit and unlock better outcomes, faster. To learn more, please visit www.optimize.health.

About Panda Health

Panda Health is a marketplace that transforms how health systems discover, procure, and implement digital innovations that make life better for consumers. Formed in 2020 as an independent company, Panda was founded through a partnership between three leading health systems, CentraCareGundersen Health System, and ThedaCare, with the development and investment firm Fitzroy Health

For media inquiries, contact:

Sunny Bjerk

[email protected] 

Contact Information:

Sunny Bjerk

Senior Director, Product Marketing
[email protected]

Press Release Service
by
Newswire.com

Original Source:

Optimize Health Joins Panda Health’s Marketplace to Deliver Leading Remote Patient Monitoring Solution to Health Systems